Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells

Wet, Larischa de; Williams, Anthony; Gillard, Marc; Kregel, Steven; Lamperis, Sophia; Gutgesell, Lisa; Vellky, Jordan E.; Brown, Roger; Conger, Kelly O.; Paner, Gladell P.; Wang, Heng; Platz, Elizabeth A.; Marzo, Angelo M. De; Mu, Ping; Coloff, Jonathan L.; Szmulewitz, Russell Z.; Griend, Donald Vander

doi:10.1038/s41388-022-02228-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies speculate that SOX2-mediated accelerated metastasis is possibly via enhanced metabolic activity. It has been reported that SOX2 expression confers high glycolysis and glycolytic capacity to PCa cells ( de Wet et al, 2022a ).…”

Section: Other Transcription Factorsmentioning

confidence: 99%

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer

Sreekumar

Saini

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Therapy-induced neuroendocrine prostate cancer (NEPC) is a highly lethal variant of prostate cancer that is increasing in incidence with the increased use of next-generation of androgen receptor (AR) pathway inhibitors. It arises via a reversible trans-differentiation process, referred to as neuroendocrine differentiation (NED), wherein prostate cancer cells show decreased expression of AR and increased expression of neuroendocrine (NE) lineage markers including enolase 2 (ENO2), chromogranin A (CHGA) and synaptophysin (SYP). NEPC is associated with poor survival rates as these tumors are aggressive and often metastasize to soft tissues such as liver, lung and central nervous system despite low serum PSA levels relative to disease burden. It has been recognized that therapy-induced NED involves a series of genetic and epigenetic alterations that act in a highly concerted manner in orchestrating lineage switching. In the recent years, we have seen a spurt in research in this area that has implicated a host of transcription factors and epigenetic modifiers that play a role in driving this lineage switching. In this article, we review the role of important transcription factors and chromatin modifiers that are instrumental in lineage reprogramming of prostate adenocarcinomas to NEPC under the selective pressure of various AR-targeted therapies. With an increased understanding of the temporal and spatial interplay of transcription factors and chromatin modifiers and their associated gene expression programs in NEPC, better therapeutic strategies are being tested for targeting NEPC effectively.

show abstract

Section: Other Transcription Factorsmentioning

confidence: 99%

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer

Sreekumar

Saini

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, they exhibit histological and clinical resemblances ( 42 ). Neuroendocrine subsets seen in late–stage cancers are poorly differentiated, with large nuclear–to–cytoplasmic ratios, that aberrantly activate stem cell gene pathways ( 34 , 43 , 44 ).…”

Section: Neuroendocrine Differentiation and Hormone Independencementioning

confidence: 99%

Editorial: Hormone resistance in cancer

Phoenix,

Budreika,

Kostlan

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells

Cited by 2 publications

References 0 publications

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer

Editorial: Hormone resistance in cancer

Contact Info

Product

Resources

About